ANDRZEJEWSKI STEPHEN J 4
4 · KING PHARMACEUTICALS INC · Filed Jan 21, 2009
Insider Transaction Report
Form 4
ANDRZEJEWSKI STEPHEN J
Chief Commercial Officer
Transactions
- Exercise/Conversion
Common Stock
2008-12-31+21,060→ 142,720 total - Award
Common Stock
2009-01-16+3,823→ 146,543 total - Exercise/Conversion
Long-Term Performance Unit
2008-12-31−21,060→ 0 totalExp: 2008-12-31→ Common Stock (21,060 underlying)
Footnotes (1)
- [F1]Each Long-Term Performance Unit represented a contingent right to receive a share of King Pharmaceuticals, Inc. common stock if the reporting person remained employed by King Pharmaceuticals, Inc. during the two-year vesting period that ended on December 31, 2008.